Study of factors linked to weight loss in amyotrophic lateral sclerosis
Collects blood samples and questionnaires from adults with amyotrophic lateral sclerosis to study weight loss.
Plain-language title generated from the registry record
Registry title: French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
Key facts
- Where
- Lille, Limoges, Marseille, Montpellier, Nice, Paris, and Tours, FranceSee the 7 sites
Where in France
- CHU de LilleLille, FranceTaking people
- Limoges university hospitalLimoges, FranceTaking people
- Hopital de la TimoneMarseille, FranceTaking people
- Hôpital Gui ChauliacMontpellier, FranceTaking people
- CHU de NiceNice, FranceTaking people
- Hôpital de la Pitié-SalpêtrièreParis, FranceTaking people
- CHU de ToursTours, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Limoges
- Trial code
- NCT06147843
- Record updated
- 6 August 2026
- Original description
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS.Read full original descriptionShow less
French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS.
Participants will undergo high quality standard care for ALS patients. In addition, participants will be asked to respond different questionnaires and blood samples will be taken for analysis to identify biological markers.
Inclusion: Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis; Incident ALS cases identified and followed-up in the participant ALS \& Other Motor Neuron Diseases Referral Centres: seven in France and two in Germany; Patients who signed the informed consent form; Adults aged >18 years old.
Exclusion: Patients who will not accept Riluzole therapy during their follow-up; Inability to understand the requirements of the protocol; Cognitive inability to sign and comprehend the informed consent form.